You are here

  • Home
  • Archive
  • Volume 38, Issue 4
  • Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

Article Text

Article menu
Download PDFPDF
Journal reviews
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

https://doi.org/10.1136/jfprhc-2012-100395

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests Kate Cuschieri has received project funding and travel grants from GlaxoSmithKline and has been an invited speaker for Sanofi Pasteur.

    • Provenance and peer review Commissioned; internally peer reviewed.